Abstract

CORRECTION OF ANEMIA WITH ERYTHROPOIESIS STIMULATING AGENTS IN CHRONIC KIDNEY DISEASE PATIENTS

Nanditha Shree H.*, Hakash R., Preethi M. S. and Nimishambha K. S.

ABSTRACT

CKD is a condition in which the kidneys are damaged and cannot filter blood as well as they should, anemia is one of the common complications of CKD. The preferred method of treating anemia caused by CKD is iron supplementation and ESAs. A descriptive study on Correction of Anemia with Erythropoiesis Stimulating Agents in Chronic kidney disease. This was a descriptive study performed on 180 patients, in the Nephrology department, Sagar hospital. It was assessed and evaluated by a suitable statistical tool. Results: Among 180 patients, 121(67.2%) were males and 59 (67.2%) were females, and more patients were observed in the age group >60. Hypertension (93.8%), DM (82.7), Hypothyroidism (75.5%) had the highest prevalence rate of risk factors. First generation ESAs were most commonly prescribed (90%) and most effective ESA compared to
second generation ESAs in treating anemia. Only 23% of the study participants experienced ADRs which were manageable. This study demonstrated that as people get older, their kidney function gradually decreases and leads to morbidity and mortality. Males are more at risk than females due to the higher rate of risk factors in the geriatric age group. The risk factors identified included DM, hypertension, hypothyroidism, IHD and CAD. Thus, anemia in CKD can be managed better by prescribing ESAs and individualization in dose helped to reduce adverse effects and promoted the safety of the patients, this guided in the better management of anemia patients with CKD.

Keywords: CKD, Anemia, Effectiveness, Efficacy, ESA.